Integrated genomic analyses of ovarian carcinoma
Комплексный геномный анализ карциномы яичника
2011-06-28
SCID: 54.1/ju8xjdvu
Discuss with AI
Cancer Genome AtlasTP53 mutationshigh-grade serous ovarian cancerhomologous recombination deficiencymolecular subtypes
Figures from the paper
Abstract (AI)
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology. The Cancer Genome Atlas (TCGA) project reports here its analysis of messenger RNA and microRNA expression, promoter methylation, DNA copy number and exome sequences in 489 high-grade serous ovarian adenocarcinomas. The analyses help establish new tumour subtypes. Among other insights is the finding that while the gene encoding p53 tumour suppressor is mutated in almost all tumours, nine other loci including NF1, BRCA1, BRCA2, RB1 and CDK12 carry recurrent albeit low-prevalence mutations. Homologous recombination is defective in about half of the tumours studied, and Notch and FOXM1 signalling are involved in the pathophysiology.
Key Findings
1
High-grade serous ovarian cancer harbors TP53 mutations in 96% of tumors, indicating near-universal disruption of the p53 pathway.
2
Homologous recombination appears defective in approximately half of tumors, while NOTCH and FOXM1 signaling contribute to serous ovarian cancer pathophysiology.
3
Integrated genomic profiling identified 113 significant focal DNA copy-number aberrations and promoter methylation events affecting 168 genes.
4
Molecular analyses defined four transcriptional, three microRNA, and four promoter-methylation subtypes, including a transcriptional signature associated with survival duration.
5
Nine additional genes, including NF1, BRCA1, BRCA2, RB1, and CDK12, carry statistically recurrent but individually low-prevalence somatic mutations.
Research Object
High-grade serous ovarian adenocarcinomas (489 tumour samples)
Research Subject
genomic and epigenomic molecular aberrations, tumour subtypes, pathway alterations, and their associations with survival and pathophysiology
Publication Details
Publication Date
2011-06-28
Journal
Publisher
ISSN
Cited by
8255
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by10
An integrated map of genetic variation from 1,092 human genomes2012
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer2012
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers2014
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study2023
Epidemiology of ovarian cancer: a review2017
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge2015
Mutational landscape and significance across 12 major cancer types2013
The Cancer Genome Atlas Pan-Cancer analysis project2013
Comprehensive genomic characterization of squamous cell lung cancers2012
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing2012